Covid-19 man­u­fac­tur­ing roundup: Scot­tish gov­ern­ment in­vests $27M in Val­neva's Covid-19 man­u­fac­tur­ing; Mod­er­na part­ners with Latin Amer­i­can phar­ma

Val­ne­va’s Scot­tish unit has re­ceived a $27 mil­lion grant to fund the R&D of man­u­fac­tur­ing its Covid-19 vac­cine VLA2001.

The in­vest­ment comes from the coun­try’s eco­nom­ic de­vel­op­ment agency. Two grants will dis­trib­ute the mon­ey over the next three years, and ben­e­fit the man­u­fac­tur­ing site in Liv­ingston.

One grant, worth $16.65 mil­lion, will sup­port R&D con­nect­ed to man­u­fac­tur­ing VLA2001. A sec­ond, worth $9.9 mil­lion, will sup­port R&D for the man­u­fac­tur­ing of oth­er dis­eases. Among those oth­er vac­cines is VLA1553, a sin­gle-shot vac­cine against the mos­qui­to-borne vi­ral in­fec­tion chikun­gun­ya. That is al­so man­u­fac­tured in Liv­ingston.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER